Inclusion Criteria:  Age: 18-75 years; ECOG (Eastern Cooperative Oncology Group) 0-1; Locally advanced or advanced recurrent hepatocellular carcinoma (HCC) that cannot be surgically removed; Have not received anti-tumor system therapy; At least 1 measurable lesion (according to RECIST 1.1); Child-Pugh Class A; At least 12 weeks of life expectancy; Adequate hematologic, hepatic and renal function: Hb ≥ 90g/L, ANC(absolute neutrophil count) ≥ 1.5x10^9/L, PLT(platelet count) ≥60 x10^9/L, ALT(alanine aminotransferase) and AST(aspartate aminotransferase) ≤3×ULN(upper limit of normal), total bilirubin ≤1.5×ULN, serum creatinine ≤1.5×ULN, albumin ≥ 30g/L; Contraception during the study; Willing to join the study and sign informed consent.  Exclusion Criteria:  HCV (hepatitis C virus) infection. History of allergy to anti-PD-1 (PD-1, programmed cell death protein 1) monoclonal antibody and anti-VEGF (VEGF, vascular endothelial growth factor) monoclonal antibody. Have other malignant tumors within 5 years, except for fully treated skin basal cell cancer and cervical cancer; Poor blood pressure control. In the case of taking medication, systolic blood pressure>140mmHg or diastolic blood pressure>90mmHg. Received radiotherapy for liver disease. History of hepatic encephalopathy. Received transplantation. Severe pleural effusion, ascites or pericardial effusion. History of autoimmune diseases and autoimmune deficiency. Receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 7 days before the first administration. Active infections that require systemic treatment, such as active tuberculosis. History of idiopathic pulmonary fibrosis, tissue pneumonia, drug-induced pneumonia or idiopathic pneumonia, or active pneumonia found in chest CT examination. Severe bleeding. Esophageal and gastric varices with high risk of bleeding and not fully treated; rupture of esophageal and gastric varices occurred within 6 months before the first administration. Required daily treatment with non-steroidal anti-inflammatory drugs (NSAID). Accompanying diseases that seriously endanger the safety of the patient or affect the completion of the study.